Landfar Bio-medicine (000504.SZ) forecasts a net profit of 12.5 million to 15.5 million yuan in 2024, turning a loss into a profit from the same period last year.

Landfar Bio-medicine (000504.SZ) has released its 2024 annual performance forecast, expecting a net profit attributable to shareholders of the listed company of 12.5 million to 15.5 million yuan for the whole year, turning losses into gains year-on-year. Reasons for the performance change: 1. During the reporting period, with the improvement of the company's financial condition and capital structure, the company's financial costs decreased significantly compared to the previous year; 2. During the reporting period, by optimizing business management, the overall profitability of the company's cell business improved compared to last year; 3. During the reporting period, the company strengthened its sales of self-operated beauty products and expanded its other product agency sales and other related derivative businesses, increasing revenue and profit sources.